Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Lenz

Showing results (11-20 of 294) with videos related to

Pageof 30
Sort By:
Leukemia & Lymphoma|April 12, 2016
Approaching resistance to ibrutinib in diffuse large B-cell lymphomaTabea Erdmann, Georg Lenz
Leukemia & Lymphoma|November 2, 2020
The role of PI3K inhibitors in the treatment of malignant lymphomasPhilipp Berning, Georg Lenz
Blood|October 20, 2022
Tackling ALK-positive LBCLFabian Frontzek, Georg Lenz
The New England Journal of Medicine|April 16, 2010
Aggressive lymphomasGeorg Lenz, Louis M Staudt
Cancer Treatment Reviews|March 18, 2018
Targeting the B-cell receptor pathway in diffuse large B-cell lymphomaKieron Dunleavy, Tabea Erdmann, Georg Lenz
Therapeutic Advances in Hematology|April 5, 2013
The molecular biology of diffuse large B-cell lymphomaMareike Frick, Bernd Dörken, Georg Lenz
Deutsche Medizinische Wochenschrift (1946)|February 5, 2020
[Current diagnostic and therapeutic standards in aggressive B-cell lymphomas]Birte Friedrichs, Norbert Schmitz, Georg Lenz
Cancer|August 27, 2004
The role of fludarabine in the treatment of follicular and mantle cell lymphomaGeorg Lenz, Wolfgang Hiddemann, Martin Dreyling
Leukemia & Lymphoma|December 28, 2022
Plasmablastic lymphoma: from genetics to treatmentFabian Frontzek, Stephan Hailfinger, Georg Lenz
Best Practice & Research. Clinical Haematology|March 14, 2012
New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphomaMareike Frick, Bernd Dörken, Georg Lenz
Pageof 30

Showing results (11-20 of 294) with videos related to

Sort By:
Pageof 30
Leukemia & Lymphoma|April 12, 2016
Approaching resistance to ibrutinib in diffuse large B-cell lymphomaTabea Erdmann, Georg Lenz
Leukemia & Lymphoma|November 2, 2020
The role of PI3K inhibitors in the treatment of malignant lymphomasPhilipp Berning, Georg Lenz
Blood|October 20, 2022
Tackling ALK-positive LBCLFabian Frontzek, Georg Lenz
The New England Journal of Medicine|April 16, 2010
Aggressive lymphomasGeorg Lenz, Louis M Staudt
Cancer Treatment Reviews|March 18, 2018
Targeting the B-cell receptor pathway in diffuse large B-cell lymphomaKieron Dunleavy, Tabea Erdmann, Georg Lenz
Therapeutic Advances in Hematology|April 5, 2013
The molecular biology of diffuse large B-cell lymphomaMareike Frick, Bernd Dörken, Georg Lenz
Deutsche Medizinische Wochenschrift (1946)|February 5, 2020
[Current diagnostic and therapeutic standards in aggressive B-cell lymphomas]Birte Friedrichs, Norbert Schmitz, Georg Lenz
Cancer|August 27, 2004
The role of fludarabine in the treatment of follicular and mantle cell lymphomaGeorg Lenz, Wolfgang Hiddemann, Martin Dreyling
Leukemia & Lymphoma|December 28, 2022
Plasmablastic lymphoma: from genetics to treatmentFabian Frontzek, Stephan Hailfinger, Georg Lenz
Best Practice & Research. Clinical Haematology|March 14, 2012
New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphomaMareike Frick, Bernd Dörken, Georg Lenz
Pageof 30